42nd week of 2009 patent applcation highlights part 30 |
Patent application number | Title | Published |
20090257925 | HOLDING SEALING MATERIAL, EXHAUST GAS PURIFYING APPARATUS, AND METHOD FOR MANUFACTURING HOLDING SEALING MATERIAL - A holding sealing material includes a mat body. The mat body includes a first inorganic fiber and a second inorganic fiber. The first inorganic fiber contains about 60% by weight or more of alumina. The second inorganic fiber contains about 67% by weight or more of silica. The first inorganic fiber and the second inorganic fiber are in a mixed state. | 2009-10-15 |
20090257926 | FLUID TREATMENT SYSTEM COMPRISING RADIATION SOURCE MODULE AND COOLING MEANS - In a fluid treatment system comprising a housing with a fluid inlet and a fluid outlet for a process fluid, an irradiation zone disposed between the fluid inlet and fluid outlet, and at least one radiation source module comprising at least one radiation source comprising a discharge vessel with an outer wall and an inner wall, the inner wall enclosing an internal volume with at least one opening and means for igniting and maintaining a discharge, the radiation source module also comprising a submersible frame with guiding means to guide the process fluid into and out of the internal volume of the radiation source. The dissipation of the heat generated by the discharge in the discharge gap via a fluid flow in the internal volume of the lamp and in contact with the internal electrodes is substantially more effective than dissipation via a cooling channel separated from the internal electrode. It is therefore substantially easier to maintain the discharge at an approximately optimal temperature. | 2009-10-15 |
20090257927 | FOLDED COAXIAL RESONATORS - A method for constructing a distributed element coaxial resonator includes folding a coaxial resonator to provide a structure having a decreased physical length compared to its electrical length. In various embodiments, the resonator is tuned to affect a standing wave when excited by a signal of a specific wavelength. The coaxial resonator includes inner, middle and outer conductor sections, wherein the characteristic impedance is maintained throughout the resonator. | 2009-10-15 |
20090257928 | Catalysts, system and method for hydrogen production - A system for producing hydrogen features a reactor including a reaction channel adapted to receive a reaction stream including a mixture of supercritical water and a hydrocarbon fuel. A catalyst is positioned in the reaction channel so that a product stream containing hydrogen is produced by a reaction in the reaction channel when the mixture is exposed to the catalyst; wherein the catalyst contains a catalytically active metal and a promoter in a metal format, selected from the group consisting of potassium, sodium, rubidium, lithium, cesium, beryllium, magnesium, calcium, strontium, and barium. | 2009-10-15 |
20090257929 | Device and method for forming macromolecule crystal - Disclosed is a macromolecule-crystal forming apparatus and method capable of obtaining a macromolecule crystal in a simplified and efficient manner. The device comprises a first container containing a sample of macromolecule, a second container containing a gel acting as a buffer material during the crystallization of the macromolecule, and a third container containing a precipitant solution having a function of facilitating the aggregation of molecules during the crystallization of the macromolecule. These containers are connected together in a given manner so as to allow the macromolecule sample and the precipitant to be brought into contact with one another through the gel to induce the crystallization of the macromolecule. | 2009-10-15 |
20090257930 | Optimized Liquid-Phase Oxidation - Disclosed is an optimized process and apparatus for more efficiently and economically carrying out the liquid-phase oxidation of an oxidizable compound. Such liquid-phase oxidation is carried out in a bubble column reactor that provides for a highly efficient reaction at relatively low temperatures. When the oxidized compound is para-xylene and the product from the oxidation reaction is crude terephthalic acid (CTA), such CTA product can be purified and separated by more economical techniques than could be employed if the CTA were formed by a conventional high-temperature oxidation process. | 2009-10-15 |
20090257931 | METHOD OF RECOVERING NOBLE METALS AND RECOVERING SYSTEM FOR NOBLE METALS - A recovering method is provided, which includes contacting a solid component containing Ru with an aqueous solution to create a Ru compound, and causing the Ru compound to selectively elute in the aqueous solution. The aqueous solution is formed of at least one selected from the group consisting of aqueous solutions A, B, C, D, and E. The aqueous solution A comprises an acid and formic acid, alcohols, aldehydes, a compound having a hemiacetal structure or a compound having an acetal structure. The aqueous solution B comprises an acid and a compound which creates, in the coexistence thereof with the acid, formic acid, alcohols, aldehydes, a compound having a hemiacetal structure or a compound having an acetal structure. The aqueous solution C comprises an acid and sugars. The aqueous solution D comprises formic acid, and the aqueous solution E comprises oxalic acid. | 2009-10-15 |
20090257932 | FLUE GAS DESULFURIZATION PROCESS - A process for desulfurizing an SO | 2009-10-15 |
20090257933 | Layered Catalyst Composite - A layered, three-way conversion catalyst having the capability of simultaneously catalyzing the oxidation of hydrocarbons and carbon monoxide and the reduction of nitrogen oxides is disclosed. In one or more embodiments, the catalyst comprises three layers in conjunction with a carrier: a first layer deposited on the carrier and comprising palladium deposited on a refractory metal oxide and an oxygen storage component; a second layer deposited on the first layer and comprising rhodium deposited on a refractory metal oxide and an oxygen storage component; and a third layer deposited on the second layer and comprising palladium deposited on a refractory metal oxide. | 2009-10-15 |
20090257934 | Transition metal - substituted hydrotalcite catalyst for removing nitrogen oxides from the exhaust gas of diesel engine by storage - reduction - Disclosed herein is a transition metal-substituted hydrotalcite catalyst for removing nitrogen oxides using a storage-reduction method, in which a molar ratio of transition metal to magnesium is 0.2 or less, and a method of manufacturing a transition metal-substituted hydrotalcite catalyst for removing nitrogen oxides using a storage-reduction method, including the steps of preparing a hydrotalcite synthesis solution including transition metal precursors such that the molar ratio of transition metal to magnesium is 0.2 or less, and preferably 0.001 to 0.2; aging the synthesis solution; and hydrothermally treating the synthesis solution. | 2009-10-15 |
20090257935 | BASE METAL AND BASE METAL MODIFIED DIESEL OXIDATION CATALYSTS - There is described a base metal modified Cerium containing oxide materials and their application as catalysts for the oxidation of CO and HC emissions from a compression ignition/diesel engine. These materials provide effective promotion of CO and HC oxidation function in the presence or absence of PGM and are based upon OIC/OS materials having a stable cubic crystal structure, and most especially to promoted OIC/OS materials wherein the promotion is achieved by the post-synthetic introduction of non-precious metals via a basic (alkaline) exchange process. | 2009-10-15 |
20090257936 | PROCESS FOR THE TREATMENT OF GAS PHASE ALKALINE CHLORIDE IN A COMBUSTION PLANT, COMBUSTION PLANT FOR CARRYING OUT THE PROCESS, AND THE USE OF A PHOSPHOROUS SUBSTANCE FOR THE TREATMENT OF ALKALINE CHLORIDE IN GASEOUS PHASE IN A COMBUSTION PLANT - A process for the treatment of gas phase alkaline chlorides in a combustion plant that is arranged for combustion of solid fuel and which includes a combustion chamber from which a flue-gas flow is directed to pass a heat transfer device. A phosphorous substance is added to the flue-gas flow, separate from the fuel, the substance chosen from a group of substances that form phosphorous oxide at combustion temperatures of approx. 500° C. or above, wherein the phosphorous substance is distributed in the flue-gas at a location upstream of the heat transfer device. The phosphorous substance is added to an amount which results in phosphatising of gas phase alkaline chlorides included in the flue-gas flow before the chlorides reach the heat transfer device. A corresponding combustion plant is disclosed, as well as the use of a phosphorous substance for phosphatising alkaline chloride in gaseous phase in a flue-gas flow. | 2009-10-15 |
20090257937 | METHOD AND APPARATUS FOR PURIFYING AND SEPARATING A HEAVY COMPONENT CONCENTRATE ALONG WITH OBTAINING LIGHT GAS ISOTOPES - The claimed method and apparatus relate to cryogenic technology, particularly to purifying and separating by distillation a target heavy component concentrate thereby obtaining target components, e.g., krypton and xenon, and isotopes of light gases such as deuterium, tritium, helium-3. The method includes temperature-stabilizing a target heavy component concentrate flow, a low-boiling target component fraction flow, and a high-boiling target component fraction flow, irradiating the flows with ionizing radiation thereby obtaining light gas isotopes, purifying the flows, concentrating the light gas isotopes in the flows with subsequently extracting thereof, purifying the production flows from nuclides, using xenon as the high-boiling target component of the concentrate and using krypton as the low-boiling target component of the concentrate. The claimed apparatus can be used for implementing the method. The method and apparatus allow for increasing the purity and safety of the production heavy target components, as well as for increasing the economic efficiency. | 2009-10-15 |
20090257938 | DESTABILIZED AND CATALYZED BOROHYDRIDE FOR REVERSIBLE HYDROGEN STORAGE - A process of forming a hydrogen storage material, including the steps of: providing a first material of the formula M(BH | 2009-10-15 |
20090257939 | METHOD FOR PURIFICATION OF SILICA PARTICLES, PURIFIER, AND PURIFIED SILICA PARTICLES - [Problems] To provide a treatment method having excellent purification effect, in which impurities having high ionicity in a silica powder can be removed in a short time, a apparatus thereof, and a purified silica powder. | 2009-10-15 |
20090257940 | ENERGY CONVERSION SYSTEM - A system of hardware and controls, know as a Hydrogen Hub, that absorbs electric power from any source, including hydropower, wind, solar, and other energy resources, chemically stores the power in hydrogen-dense anhydrous ammonia, then reshapes the stored energy to the power grid with zero emissions by using anhydrous ammonia to fuel diesel-type, spark-ignited internal combustion, combustion turbine, fuel cell or other electric power generators. | 2009-10-15 |
20090257941 | Coal/Coke/Heavy Residual Oil Boiler With Sulfur And Carbon Dioxide Capture And Recovery - A pulverized coal/coke (PC) boiler combusts carbon-based fuel with substantially pure oxygen and a flue gas recirculation stream (containing predominately carbon dioxide) at varied ratios to achieve a desired boiler temperature profile while producing captured sulfur, a high purity captured CO | 2009-10-15 |
20090257942 | DEVICE AND METHOD FOR GROWING DIAMOND IN A LIQUID PHASE - A method of growing a diamond mass in a liquid growth medium. The liquid growth medium can include a carbon source, a diamond growth catalyst such as a diamond catalyst metal-rare earth element alloy or nanocatalyst, and a dissociated hydrogen of a hydrogen source. The carbon source provides carbon atoms for growing diamond and can include a diamond seed material for diamond growth. The molten liquid phase provides a diamond growth catalyst which allows the carbon to form diamond at the temperature and low pressure conditions discussed. Furthermore, the dissociated hydrogen acts as a concentrator for assembling carbon atoms at a relatively high concentration which mimicks, in some respects, diamond growth under more conventional high pressure processes without the high pressure. | 2009-10-15 |
20090257943 | Method of Selective Purification of Armchair Carbon - The present invention provides a method of selectively extracting metallic armchair carbon nanotubes alone from the mixture of carbon nanotubes of mixed chiralities, wherein vacant lattice defects are removed from armchair carbon nanotubes alone using the fact that the vacant lattice defects of zigzag carbon nanotubes are hard to diffuse in the axial direction of nanotubes compared with those of armchair carbon nanotubes. Since vacant lattice defects remaining on zigzag carbon nanotubes are active, the tube structures are easily destroyed and decomposed by oxidation etc. Thus it is possible to extract armchair carbon nanotubes alone from the mixture of carbon nanotubes of mixed chiralities. | 2009-10-15 |
20090257944 | METHOD FOR PRODUCING CARBON NANOTUBE - A method for producing carbon nanotubes uses a polymer as a raw material to undergo in situ thermal decomposition. The method includes steps of mixing the polymer and metallic catalyst through a multiple heating stage process of in-situ thermal decomposition to carbonize the polymer and release carbon elements to produce carbon nanotubes. Advantages of the present invention include easy to prepare, low temperature in manipulation, low production cost, and high safety. | 2009-10-15 |
20090257945 | METHODS OF MAKING HORIZONTALLY ORIENTED LONG CARBON NANOTUBES AND APPLICATIONS OF SAME - An apparatus and method for synthesizing nanostructures in a reactor having a reaction zone and a conductive susceptor positioned in the reaction zone. In one embodiment, the method has the steps of placing a semiconductor plate having a film of a catalyst in the reaction zone such that the semiconductor plate is supported by the conductive susceptor; transporting a gas mixture having a feedstock gas having hydrocarbon and a carrier gas into the reaction zone of the chamber; inductively heating the reaction zone; and regulating the heating so that the temperature of the conductive susceptor increases from a first temperature to a second temperature when the gas mixture is introduced into the cavity of the chamber to allow nanostructures to be grown from the interaction of the gas mixture with the film of a catalyst of the semiconductor plate. | 2009-10-15 |
20090257946 | METHOD AND APPARATUS FOR PRESSURIZED CALCINATION OF GYPSUM - A method for calcining gypsum in a pressurized reactor by injecting combustion gases and air into the pressurized reactor to create a fluidized bed of gypsum, and heating the fluidized bed of gypsum in the pressurized reactor sufficiently to form a calcined hemihydrate. | 2009-10-15 |
20090257947 | Method of manufacturing zinc aluminate nano-material - A method for making zinc aluminate nano-material, the method comprises the following steps. Firstly, providing a growing substrate and a growing device, and the growing device comprising a heating apparatus and a reacting room. Secondly, placing the growing substrate and a quantity of reacting materials into the reaction room, and the reacting materials comprising zinc and aluminum. Thirdly, introducing an oxygen-containing gas into the reaction room. Lastly, heating the reaction room to a temperature of 660˜1100° C. | 2009-10-15 |
20090257948 | Synthesis of Zeolites from Fly Ash - A process with fusion pre-treatment for synthesizing geopolymers and zeolites from fly ash, in particular X-type zeolites with pores of large dimensions and high capacity that utilize sea water and low incubation temperatures. Fly ash is initially mixed with NaOH to obtain a mixture, which is pulverized and then melted at the temperature of 550° C. After cooling, the melted mass is pulverized dispersed in sea water with fixed ratios and left under stirring at ambient temperature for 12 hours. The incubation of the ground material in sea water takes place at a temperature of between 25 and 70 degrees centigrade. Once the incubation period is ended, the solid part is separated from the liquid phase (sea water) through centrifugation and subsequently rinsed and oven dried. | 2009-10-15 |
20090257949 | Radiopharmaceutical Imaging of Neurodegenerative Diseases - Methods for simultaneously detecting dementia or cognitive impairment, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Lewy Body Dementia (LBD) and Vascular Dementia (VaD) in a patient using dual or multiple radiopharmaceutical probes are provided herein. | 2009-10-15 |
20090257950 | Membrane Scaffold Proteins - The membrane scaffold proteins (MSP) of the present invention assemble with hydrophobic or partially hydrophobic proteins to form soluble nanoscale particles which preserve native structure and function; they are improved over liposomes and detergent micelles, both in terms of stability and preservation of biological activity and native conformation. In the presence of phospholipid, MSPs form nanoscopic phospholipid bilayer disks, with the MSP stabilizing the particle at the perimeter of the bilayer domain. The particle bilayer structure allows manipulation of incorporated proteins in solution or on solid supports, including for use with such surface-sensitive techniques as scanning probe microscopy or surface plasmon resonance. The nanoscale particles, which are robust in terms of integrity and maintenance of biological activity of incorporated proteins, facilitate pharmaceutical and biological research, structure/function correlations, structure determinations, bioseparations, and drug discovery. | 2009-10-15 |
20090257951 | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same - The present invention provides a method of identifying a tumor homing molecule that homes to angiogenic vasculature by contacting a substantially purified NGR receptor with one or more molecules and determining specific binding of a molecule to the NGR receptor, where the presence of specific binding identifies the molecule as a tumor homing molecule that homes to angiogenic vasculature. The invention also provides a method of directing a moiety to angiogenic vasculature in a subject by administering to the subject a conjugate including a moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor, whereby the moiety is directed to angiogenic vasculature. In addition, the invention provides a method of imaging the angiogenic vasculature of a tumor in a subject by administering to the subject a conjugate having a detectable moiety linked to a tumor homing molecule that exhibits specific binding to an NGR receptor and detecting the conjugate. | 2009-10-15 |
20090257952 | Engineered Integrin Binding Peptides - Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α | 2009-10-15 |
20090257953 | NOVEL FLUORINE-18 LABELED RHODAMINE DERIVATIVES FOR MYOCARDIAL PERFUSION IMAGING WITH POSITRON EMISSION TOMOGRAPHY - The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents. | 2009-10-15 |
20090257954 | Development of a simple animal model for infection by viruses and other obligate intracellular parasites - The present invention provides methods for studying pathogenesis of mammalian viruses. In particular, the present invention provides a nonhuman animal model system for studying disease mechanisms wherein the nonhuman animal model is infected with an animal virus. In a preferred embodiment the animal model is | 2009-10-15 |
20090257955 | Sheep model of neuropathic pain behavior and uses thereof - Methods for producing peripheral nerve injury in sheep are provided. The sheep model provides a model of persistent neuropathic pain in humans. Methods for drug delivery are provided. Also provided is a method for screening potentially therapeutic agent for the treatment of persistent neuropathic pain. Also provided are the methods for measuring the changes produced by neuropathic pain. | 2009-10-15 |
20090257957 | Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders - This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention. | 2009-10-15 |
20090257958 | PESTICIDAL COMPOSITIONS - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations. | 2009-10-15 |
20090257959 | PESTICIDAL COMPOSITIONS - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations. | 2009-10-15 |
20090257960 | NEUTRALIZED ACID GROUP-CONTAINING POLYMERS AND THE USE THEREOF - The present invention relates to a polymer component which consists of one polymer or of a plurality of different polymers, comprises at least one polyurethane, where the polymer or at least one of the polymers has acid groups which are neutralized partially with at least one inorganic base and partially with at least one organic base, to cosmetic or pharmaceutical compositions which comprise such a polymer component, and to a method of modifying the mechanical properties of such a polymer component, in which, for the neutralization, at least one inorganic base and at least one organic base are used. | 2009-10-15 |
20090257961 | DENTURE CARE COMPOSITION - This invention relates to a new denture care composition and method of use. In particular, this invention relates to a film-forming denture care composition that kills odor causing bacteria, maintains prolonged fresh breath for two or more hours and is an effective guard against denture odor. | 2009-10-15 |
20090257962 | Compositions for human dental care - Compositions of the invention are water-based formulas that contain natural ingredients which aid in reduction of bacteria in the mouth, thereby reducing plaque and the production of tartar, and in one aspect of the invention are formulated as potable dental water that may be consumed in place of regular consumption of other forms of water or liquid, and in another aspect of the invention are formulated as dentifrices, such as toothpaste. | 2009-10-15 |
20090257963 | METHOD FOR MEASURABLY IMPROVING ORAL HEALTH - A composition for measurably improving oral health, a system including the composition, a method of using the composition and system, and a method of forming the composition and system are disclosed. The composition is a gel that maintains contact with a portion of an oral cavity for an extended period of time to, for example, prevent or reduce plaque and calculus buildup. The system includes a composition and a container encapsulating the composition. The composition is applied by rupturing the container and applying the composition through the ruptured portion of the container. In exemplary embodiments, the methods, systems and kits disclosed herein are suitable for measurably reducing an amount of gingivitis, periodontitis, bleeding, plaque and/or tartar. | 2009-10-15 |
20090257964 | Fluoride-releasing strips for caries prevention - The present invention discloses fluoride-releasing strips for caries prevention, wherein the fluoride-releasing strips comprises a colloidal fluoride-containing solution for releasing fluorine ion and a support substrate. A colloidal fluoride-containing solution comprises a fluoride solution, at least one buffer, at least one moisturizer and a carboxymethyl cellulose (CMC). The concentration of fluoride ions in said colloidal fluoride-containing solution ranges from 2500 ppm to ppm. The support substrate is waterproof material and the colloidal fluoride-containing solution is applied on the support substrate. | 2009-10-15 |
20090257965 | ABNORMAL PROTEIN REMOVING COMPOSITION - Provide an effective composition for removing abnormal protein. Also, a composition for removing abnormal protein whose main ingredient is soyasaponin B group, which is used to provide a composition, agent or food contributing to the prevention or treatment of diseases caused by proteolysis abnormality, among others. | 2009-10-15 |
20090257966 | TERNARY AND QUATERNARY WAX-RESIN COMPOSITES FOR USE IN COSMETIC AND PHARMACEUTICAL PREPARATIONS - A wax-resin composite is made by melting thermoplastic hydrocarbon resin, optionally with an antioxidant. The melted thermoplastic hydrocarbon resin and waxes are blended at a temperature sufficient to melt the waxes. After blending and melting, the blended thermoplastic hydrocarbon resin and waxes are allowed to solidify. Solidification is followed by post-processing the wax-resin composite mixture to form slabs, pastilles, flakes or other forms. A method for producing a wax-resin composite comprises at least partially solvating a thermoplastic resin in a solvent to form a resin-solvent blend. This may be done at a heat of 80-85° C. A composition of molten wax is blended with the resin-solvent blend. The resin-solvent blend and a molten wax are blended to form a wax-resin blend. This is followed by removing the solvent from said wax-resin blend. | 2009-10-15 |
20090257967 | Compositions comprising sugar beet pectin and carotenoids - Carotenoid compositions for use as colorants or additions for food, animal feeds, cosmetics or drugs comprise finely dispersed carotenoids in a sugar beet matrix. | 2009-10-15 |
20090257968 | Gels containing anionic surfactants and coupling agents - The present invention provides an enhanced gelling agent composition comprising a mixture of an anionic surfactant and a coupling agent. The invention also describes compositions in gel form comprising: (a) a solvent selected from the group consisting of polar solvents, non-polar solvents and combinations thereof; and (b) a gelling agent in an amount sufficient to impart gelation to the composition, the gelling agent being a mixture comprising an anionic surfactant and a coupling agent. The gels of the invention may be substantially anhydrous or may optionally contain water as part of the formulation. | 2009-10-15 |
20090257969 | SOFT ANTICHOLINERGIC ZWITTERIONS - Soft anticholinergic zwitterions of the formulas: | 2009-10-15 |
20090257970 | ANTIPERSPIRANT COMPOSITIONS CONTAINING A COPPER SALT AND A PENETRATION ENHANCER AND METHODS OF USING THE SAME - Antiperspirant compositions including a copper salt and a penetration enhancer are described. The penetration enhancer may be salicylic acid or urea. In addition to a copper salt, the composition may also comprise an aluminum or zirconium salt. Methods of using the compositions are also described. Embodiments may be useful in treating perspiration, hyperhidrosis, and associated undesirable odors of the axillae, hands, feet, lower back, groin, and other areas. | 2009-10-15 |
20090257971 | Antiperspirant composition - An antiperspirant composition with the antiperspirant composting containing a thickening agent in sufficient quantity so as to produce an antiperspirant composition wherein the viscosity is less than 2400 centpoises. | 2009-10-15 |
20090257972 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS IN PARTICULAR FOR THE TREATMENT OF KERATIN CONTAINING SUBSTRATES - The present invention relates to cosmetic and/or dermatological compositions for the treatment of keratin containing substrates, comprising synergistic mixtures of modified starch polymers with defined molecular weights and cationic charges in a cosmetically acceptable medium. The synergistic mixtures of modified starches employed to manufacture compositions according to the present invention exhibit significant benefits over the existing modified starches employed according to the state-of-the-art in the treatment of keratin-containing substrates like human or animal hair, skin and nails. Another aspect of the present invention is the stabilization of the modified starch solutions used to manufacture the cosmetic and/or dermatological compositions according to the present invention against the growth of micro-organisms without traditional preservatives. | 2009-10-15 |
20090257973 | MALODOR REDUCING COMPOSITION, FRAGRANCE COMPOSITION AND PRODUCT COMPRISING THE SAME - The invention relates to a malodor reducing composition comprising:
| 2009-10-15 |
20090257974 | Perfume Compositions - Perfume compositions comprise between 10% and 30% in total by weight of perfume ingredients selected from two groups, Group A, Group B, with the provisos that over 5% but less than 15% of the perfume composition must comprise Group A ingredients, and for compositions comprising less than 10% of Group A ingredients the agregate percentage of Group B ingredients present must be at least equal to the expression 2*/10-A%) where A% is the total percentage of Group A ingredients in the composition. | 2009-10-15 |
20090257975 | Solid and Semi-Solid Polymeric Ionic Conjugates - Aqueous solubility of drugs including insoluble or poorly soluble drugs such as ziprasidone is improved using a functional polymer to form an ionic conjugate with said drug. | 2009-10-15 |
20090257976 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE - Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate. | 2009-10-15 |
20090257977 | NOVEL TETRAHYDROPYRIDOTHIOPHENES - Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity. | 2009-10-15 |
20090257978 | Antiviral coumpounds - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2009-10-15 |
20090257979 | Novel Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2009-10-15 |
20090257980 | ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES - The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose. | 2009-10-15 |
20090257981 | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same - Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies. | 2009-10-15 |
20090257982 | MEDICAL DEVICE FOR TREATING DIABETES MELLITUS, OBESITY, CHRONIC FATIGUE, AGING, AND OTHER MEDICAL CONDITIONS BY UTILIZING MODIFIED VIRUS VIRIONS TO INSERT MESSENGER RIBONUCLEIC ACID MOLECULES INTO CELLS - The common link between diabetes mellitus, obesity, chronic fatigue and even aging may be related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration. Utilizing a medical device comprised of a modified form of virus to deliver to cells in the body the messenger RNA molecules needed to construct insulin receptors and generate the enzymes that participate in the processes of glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation and anaerobic respiration will lead to greater utilization of blood glucose and a more efficient and sustained production of the energy molecules that fuel the metabolic processes of the cell. Greater utilization of blood glucose will significantly advance the effort to correct the medical problems associated with diabetes, obesity, chronic fatigue, and aging. | 2009-10-15 |
20090257983 | MEDICAL TREATMENT DEVICE FOR TREATING AIDS BY UTILIZING MODIFIED HUMAN IMMUNODEFICIENCY VIRUS VIRIONS TO INSERT ANTI-VIRAL MEDICATIONS INTO T-HELPER CELLS - The medical device by which a modified Human Immunodeficiency Virus or virus-like structure is used as a transport medium to carry a payload of a quantity of anti-viral drug molecules to T-Helper cells in the body. The modified Human Immunodeficiency Virus or virus-like structure makes contact with a T-Helper cell by means of the modified virus's exterior probes or virus-like structure's exterior probes. Once the exterior probes engage the T-Helper cell's receptors, the modified virus or virus-like structure inserts into the T-Helper cell the quantity of medically therapeutic anti-viral drug molecules it is carrying. The anti-viral drug molecules exhibit an anti-viral effect when present inside the T-Helper cells thus assisting in repelling an infection by the Human Immunodeficiency Virus and the use of such a device significantly lowers the occurrence of unwanted deleterious side effects. | 2009-10-15 |
20090257984 | ANTIFUNGAL COMPOSITIONS CONTAINING THE ENDOPHYTE FUNGUS ALTERNARIA ALTERNATA AND OR ITS METABOLITES, AS ANTAGONIST AGENTS OF PLASMOPARA VITICOLA - The present invention relates to compositions containing the fungus | 2009-10-15 |
20090257985 | METHODS OF REGULATING EXPRESSION OF GENES OR OF GENE PRODUCTS USING SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention relates, at least in part, to the use of substituted tetracycline compounds for regulation of expression of nucleic acids operably linked to a tetracycline operator system. The invention pertains to compounds used in a regulatory system which utilizes components of the Tet repressor/operator/inducer system of prokaryotes to regulate gene expression in cells. Use of certain substituted tetracycline compounds, as featured in the methods of the invention, result in improved dose-response results when compared to those for e.g., tetracycline and doxycycline. Certain methods of the invention thus allow for enhanced control of the Tet repressor/operator/inducer system in regulating gene expression in cells. | 2009-10-15 |
20090257986 | EPIDERMAL AND DERMAL EQUIVALENTS - The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein. | 2009-10-15 |
20090257987 | Method of generating dopamine-secreting cells - Methods of generating cells which secrete dopamine are disclosed. One method comprises incubating mesenchymal stem cells in a culture medium comprising brain derived neurotrophic factor (BDNF), wherein the culture medium comprises no more than 0.1 μM retinoic acid (RA). Another method comprises incubating mesenchymal stem cells in a culture medium comprising glial-derived neurotrophic factor GDNF, transforming growth factor β3 (TGFβ3) and retinoic acid (RA). Cells generated by the above-described methods are also disclosed as well as uses thereof. | 2009-10-15 |
20090257988 | METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY T CELLS EX VIVO - The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses. | 2009-10-15 |
20090257989 | Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 2009-10-15 |
20090257990 | Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues - Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided. | 2009-10-15 |
20090257991 | Engineering and Delivery of Therapeutic Compositions of Freshly Isolated Cells - The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing. | 2009-10-15 |
20090257992 | ADJUNCTIVE AGENT FOR LAVAGING THE ALIMENTARY CANAL COMPRISING BUTYRIC ACID BACTERIUM AND/OR LACTIC ACID BACTERIUM - The present invention provides an adjunctive agent for lavaging the alimentary canal which is able to reduce a dose of oral cleaning agent for lavaging the alimentary canal, and is capable of realizing an excellent cleaning effect at the time of use of the aforementioned oral cleaning agent for lavaging the alimentary canal. The means for solving the problem is an adjunctive agent for lavaging the alimentary canal which is comprising butyric acid bacterium (for example, | 2009-10-15 |
20090257993 | Lactic Acid Producing Bacteria and Lung Function - The present invention provides novel use for live (probiotic) lactic acid producing bacteria, dead or non-viable bacteria thereof, as well as food supplements, nutritive compositions and/or pharmaceutical compositions comprising these, for the treatment or prophylaxis of lung dysfunction in a subject. A suitable lactic acid producing bacterium has a significant beneficial effect on airway narrowing determined by measuring the enhanced pause value (Penti) of a test animal. | 2009-10-15 |
20090257994 | Chimeric immunoreceptor useful in treating human cancers - The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain. | 2009-10-15 |
20090257995 | HARMFUL BACTERIUM CONTROL AGENT CONTAINING BACILLUS THURINGIENSIS - Through inhibition of the multiplication of pathogenic bacteria and inactivation of bacterial self-induced factors, the balance of intestinal flora is improved to thereby promote regulation of animal intestinal functions and enable prevention/treatment of infection disease caused by such pathogenic bacteria. Accordingly, a pharmaceutical containing | 2009-10-15 |
20090257996 | DIETARY SUPPLEMENT ENERGY-PROVIDING TO SKELETAL MUSCLES AND PROTECTING THE CARDIO VASCULAR TRACT - Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines. | 2009-10-15 |
20090257997 | Stable Aqueous Compositions Comprising Bioactive Creatine Species - Compositions containing one or more bioactive forms of creatine which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creating O-phosphate species to a mammalian subject, either chronically or acutely. | 2009-10-15 |
20090257998 | METHOD FOR TREATING HEART ATTACKS, STROKES AND DIABETIC CRISIS BY UTILIZING MODIFIED VIRUS VIRIONS TO INSERT NECESSARY PROTEIN MOLECULES AND VITAL NUTRIENTS INTO TARGETED CELLS - The common link between incurring a heart attack, suffering a stroke or diabetic crisis is related to deficiencies involving a body's metabolism of glucose and the ability to optimally conduct the necessary biologic processes of aerobic respiration to produce energy molecules. Utilizing a medical treatment method comprised of a modified form of virus to deliver to cells in the body the protein molecules and nutrients needed to enhance the processes of glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation and anaerobic respiration will save lives. Providing an alternative means for brain cells and heart muscle cells to have access to proteins, nutrients such as glucose and oxygen, and energy molecules by providing these tissues with viruses that carry these vital elements to these tissues will greatly improve the survivability of individuals experiencing a heart attack, a stroke or a diabetic crisis. | 2009-10-15 |
20090257999 | Method of preventing contrast-induced nephropathy - The present invention relates to methods of preventing contrast-induced nephropathy including the step of administering an effective amount of a compound (e.g., a peroxynitrite decomposition agent, a PARP inhibitor or a superoxide dismutase mimic) to a subject to be administered a contrast agent. | 2009-10-15 |
20090258000 | MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS - The present invention is directed to compositions and methods for non-irritatively treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves compositions including a mucosally non-irritative mixture of amphotericin B and a pharmaceutically acceptable carrier. Such compositions can be non-irritatively mucoadministered to prevent, reduce, or eliminate chronic non-invasive fungus-induced mucositis conditions. | 2009-10-15 |
20090258001 | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases - A method of treating an autoimmune disease, such as, diabetes or psoriasis, by administering an anti-CD3 antibody, or anti-CD3 antibody fragment. The anti-CD3 antibody, or antibody fragment, is administered over a course of treatment wherein, during the course of treatment, the anti-CD3 antibody, or anti-CD3 antibody fragment is administered in a total amount which does not exceed 300 μg/kg when administered intravenously or, when administered other than intravenously, is administered in a total amount that does not exceed a total amount bioequivalent to 300 μg/kg of intravenous administration thereof. | 2009-10-15 |
20090258002 | Biomarkers for Tissue Status - The invention relates to methods of accurately and quickly diagnosing and monitoring the progression of cancer and ischemally injured tissue. The invention also provides methods of treatment as well as methods of screening for compositions useful for treating the disorders. | 2009-10-15 |
20090258003 | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof - The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular VT and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2009-10-15 |
20090258004 | HUMAN BLOOD PROTEINS EXPRESSED IN MONOCOT SEEDS - The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them. | 2009-10-15 |
20090258005 | Therapeutic compositions and methods - The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2. | 2009-10-15 |
20090258006 | METHOD OF MODULATING NEOVASCULARIZATION - The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in an amount effective to inhibit neovascularization. The invention also provides a method of identifying an agent that inhibits neovascularization. The method comprises detecting fibronectin (Fn) matrix assembly by stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A decrease in Fn matrix assembly in the presence of the agent compared to Fn matrix assembly in the absence of the agent is indicative of an agent that inhibits neovascularization. Alternatively, the method of identifying an agent that inhibits neovascularization comprises detecting changes in nuclear architecture in stimulated endothelial cells cultured in three-dimensional culture gel in the presence and absence of an agent. A reduction in nuclear architecture organization identifies an agent that inhibits neovascularization. | 2009-10-15 |
20090258007 | Anti-Perp Antibody - The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP. | 2009-10-15 |
20090258008 | Uses of the FcRn Receptor - The invention relates to the field of biochemistry and molecular biology. More specifically the invention relates to the production of (monoclonal) antibodies and even more specifically to the production of therapeutic and diagnostic antibodies. The invention provides a method for producing an antibody or a functional part, derivative and/or analogue thereof in a cell, comprising providing a cell that is capable of producing said antibody with FcRn receptor protein and culturing said cell to allow for production of said antibody. | 2009-10-15 |
20090258009 | PROTOFIBRIL SELECTIVE ANTIBODIES AND THE USE THEREOF - The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(CIq) binding, effective in clearance of Aβ protofibrils and with reduce risk of inflammation. | 2009-10-15 |
20090258010 | METHODS, COMPOSITIONS, AND KITS FOR TREATING SHIGA TOXIN ASSOCIATED CONDITIONS - The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies. | 2009-10-15 |
20090258011 | Antibodies against west nile virus and therapeutic and prophylactic uses thereof - The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions. | 2009-10-15 |
20090258012 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders. | 2009-10-15 |
20090258013 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2009-10-15 |
20090258014 | COMBINATION OF HGF INHIBITOR AND EGF INHIBITOR TO TREAT CANCER - The present invention is directed toward a method of treating cancer by administering to a patient an inhibitor of Hepatocyte Growth Factor and an inhibitor of, e.g., Epidermal Growth Factor. | 2009-10-15 |
20090258015 | Modulators of Candida Hyphal Morphogenesis and Uses Thereof - The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof. | 2009-10-15 |
20090258016 | Substituted imidazole derivatives - The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: | 2009-10-15 |
20090258017 | Lyophilized therapeutic peptibody Formulations - The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody. | 2009-10-15 |
20090258018 | Methods for treating juvenile idiopathic arthritis - The invention provides methods and compositions for the treatment of juvenile idiopathic arthritis (JIA) where a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat JIA. In particular, the invention is directed to methods and compositions relating to a fixed dosing regimen for treating JIA with a TNFα inhibitor. | 2009-10-15 |
20090258019 | Diagnosis of carcinoma using RAIG1 polypeptides - The present invention relates to the new uses of a polypeptide (retinoic acid-inducible gene 1; RAIG1, also known as hypothetical protein FLJ10899 or retinoic acid induced 3) compositions comprising the polypeptide, including vaccines, antibodies that are immunospecific for the polypeptide and agents which interact with or modulate the expression or activity of the polypeptide or the expression of the nucleic acid which encodes the polypeptide. The use of the polypeptide in the diagnosis, screening and treatment of carcinoma, e.g. breast cancer, pancreatic cancer, lung cancer, liver cancer, ovarian cancer, colon cancer and/or osteosarcoma, is also provided. | 2009-10-15 |
20090258020 | ANTIBODY DESIGNATED BARB3, BARB3 RELATED ANTIBODIES, AND METHODS OF MAKING AND USING SAME - The invention provides antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions. Antibodies, functional fragments, modified and variant forms, nucleic acid and other compositions are useful in treatment and diagnostic methods. One treatment method includes inhibiting growth or proliferation of proliferating cells, such as hyperproliferative cells or inducing regression of hyperproliferative cells, such as cells of a cellular hyperproliferative disorder. | 2009-10-15 |
20090258021 | GENES ASSOCIATED WITH MECHANICAL STRESS, EXPRESSION PRODUCTS THEREFROM, AND USES THEREOF - The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment, prevention, or control, of osteoporosis or fractures; and to diagnostic, treatment, prevention, or control methods or processes, as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors. | 2009-10-15 |
20090258022 | ANTIBODIES TO BRAIN SPECIFIC MEMBRANE PROTEIN - A novel gene apparently encoding a transmembrane glycoprotein has been successfully isolated by constructing a cDNA library of 4 kb or above in size from mRNA expressed in human adult brain and analyzing the structures of the cDNAs contained within said library by the shotgun method. The novel gene shows brain-specific expression and the protein encoded by said gene has a typical PDZ binding motif. | 2009-10-15 |
20090258023 | TGF-BETA SUPERFAMILY BINDING PROTEINS AND MODULATION OF BONE FORMATION AND LOSS - The present invention relates to novel polynucleotides and polypeptides that are expressed in osteoblasts, interact with members of the TGF-β superfamily, and inhibit mineralization. The invention further relates to the use of these polynucleotides and polypeptides to modulate bone formation and bone loss. | 2009-10-15 |
20090258024 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC INFLAMMATORY DISEASES - This invention relates to methods and compositions for diagnosis and treatment of chronic inflammatory diseases by blocking CD147 interaction with extracellular cyclophilin. Specifically, the methods and compositions of this invention regulate recruitment of leukocyte to the infection site by specifically blocking the CD147 domain involved with the chemotactic function without blocking the CD147 domain involved with EMMPRIN function. | 2009-10-15 |
20090258025 | TREATMENTS AND DIAGNOSTICS FOR CANCER, INFLAMMATORY DISORDERS AND AUTOIMMUNE DISORDERS - Methods for the treatment of cancer with therapies targeting tumor-associated macrophage activities are provided. Methods for the treatment of cancer, inflammatory and autoimmune disorders with therapies using tumor-associated macrophages and adipose tissue macrophages are also provided. | 2009-10-15 |